A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Avitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 26 Jun 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2019.
- 26 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Dec 2017.
- 22 Feb 2017 New trial record